Results 241 to 250 of about 233,946 (332)

Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study

open access: yesBritish Journal of Haematology, Volume 208, Issue 5, Page 1713-1723, May 2026.
Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for severe combined immunodeficiency (SCID). Conditioning improves donor engraftment and freedom from immunoglobulin replacement (IgR) but increases the risks of acute and late toxicity. Treosulfan, a reduced toxicity alkylating agent, has emerged as an alternative
Su Han Lum   +15 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Splenectomy in β‐thalassemia patients: Practices and risks in a nationwide study

open access: yes
HemaSphere, Volume 10, Issue 5, May 2026.
Audrey Benoit   +194 more
wiley   +1 more source

Common Gynecologic Issues in Patients Post‐Kidney Transplantation

open access: yesClinical Transplantation, Volume 40, Issue 5, May 2026.
ABSTRACT Advances in kidney transplantation have transformed survival and quality of life for women with end‐stage renal disease, necessitating a focus on long‐term health care for this population. Female kidney transplant recipients (KTR) experience a unique spectrum of gynecologic issues shaped by persistent hormonal dysregulation, lifelong ...
Mary Elaine Graham   +4 more
wiley   +1 more source

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Ye Yuan   +7 more
wiley   +1 more source

Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study

open access: yesDiabetic Medicine, Volume 43, Issue 5, May 2026.
In a nationwide cohort of 10,614 patients with metabolic dysfunction–associated steatotic liver disease (MASLD) hospitalized for cardiovascular disease (CVD), diabetes was present in 4550 patients (43%) and was independently associated with higher in‐hospital mortality and cardiovascular complications.
Soichi Komaki   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy